Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company focused on early cancer detection, closed its previously announced follow-on offering. The offering consisted of 1,367,521 units, each including one ordinary share (or prefunded warrant), one Class A warrant, and one Class B warrant. Gross proceeds totaled approximately $8.0 million, with each unit priced at $5.85. This at-the-market pricing adhered to Nasdaq rules. Both Class A and Class B warrants are immediately exercisable at $5.85 per share. Class A warrants expire in five years, while Class B warrants expire either 30 days after the Company’s eAArly Detect 2 study results or one year from issuance, whichever comes first.

Maxim Group LLC served as the sole placement agent.

The securities were offered under a registration statement (Form F-1, File No. 333-282993), declared effective by the SEC on December 12, 2024. The offering was conducted via a prospectus included in the Registration Statement, which has been filed with the SEC. Copies are available from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, (212) 895-3745. This press release does not constitute an offer or solicitation to buy or sell securities where prohibited by law.

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information

About Mainz Biomed NV
Mainz Biomed develops molecular genetic diagnostic tools for serious illnesses. Its flagship product, ColoAlert^®, is a non-invasive colorectal cancer early detection test marketed in Europe and currently undergoing pivotal FDA clinical trials for US approval. The company also develops PancAlert, a pancreatic cancer screening test. For more details, visit mainzbiomed.com.

For media inquiries

MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
mainzbiomed@mc-services.eu

For investor inquiries, please contact info@mainzbiomed.com

Forward-Looking Statements

This press release contains forward-looking statements, subject to risks and uncertainties under the Private Securities Litigation Reform Act of 1995. These statements, which may include words like “anticipate,” “believe,” “expect,” etc., reflect current analysis and are not guarantees of future results. Actual results could differ materially due to factors such as unmet development targets, regulatory changes, the impact of the COVID-19 pandemic, and other risks detailed in the Company’s SEC filings, including its Form 20-F filed April 9, 2024, available at www.sec.gov. These statements speak only as of today’s date, and Mainz Biomed disclaims any obligation to update them unless required by law.

“`